Literature DB >> 26943788

The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories.

Massimo Milione1, Patrick Maisonneuve, Francesca Spada, Alessio Pellegrinelli, Paola Spaggiari, Luca Albarello, Eleonora Pisa, Massimo Barberis, Alessandro Vanoli, Roberto Buzzoni, Sara Pusceddu, Laura Concas, Fausto Sessa, Enrico Solcia, Carlo Capella, Nicola Fazio, Stefano La Rosa.   

Abstract

BACKGROUND/AIMS: Gastroenteropancreatic (GEP) neuroendocrine carcinomas (NECs) are defined as neuroendocrine neoplasms (NENs) with a Ki-67 index >20% according to the 2010 WHO classification. Some reports suggest that this category is heterogeneous. We retrospectively studied a series of 136 patients affected by grade 3 GEP-NECs with the aim to clarify the prognostic role of tumor morphological differentiation, proliferation, defect in mismatch repair proteins (MMRd), CD117 expression, and site of origin. The primary endpoint was the correlation between these parameters and the overall survival (OS).
METHODS: Univariate and multivariable Cox proportional hazards regression analyses were used to assess the prognostic significance of various clinical and histopathologic features.
RESULTS: With a median follow-up of 81 months, the median OS was 12.9 months. At multivariate analysis, morphological differentiation, Ki-67 index, MMRd, stage, and CD117 expression were independent prognostic markers in NECs. Three different prognostic categories of NECs were identified according to the degree of morphologic differentiation (well vs. poorly differentiated) and Ki-67 index (<55% vs. ≥55%). On this basis, median OS was 43.6 months in well-differentiated neoplasms with a Ki-67 index 20-55% (named type A), 24.5 months in poorly differentiated neoplasms with a Ki-67 index 20-55% (type B), and 5.3 months (p < 0.0001) in poorly differentiated neoplasms with a Ki-67 index ≥55% (type C).
CONCLUSIONS: The present study suggests that GEP-NECs represent a heterogeneous group of neoplasms which can be better classified in different prognostic categories using both tumor morphology and Ki-67 index.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26943788     DOI: 10.1159/000445165

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  68 in total

Review 1.  Pancreatic neuroendocrine tumors: A review of serum biomarkers, staging, and management.

Authors:  Zu-Yi Ma; Yuan-Feng Gong; Hong-Kai Zhuang; Zi-Xuan Zhou; Shan-Zhou Huang; Yi-Ping Zou; Bo-Wen Huang; Zhong-Hai Sun; Chuan-Zhao Zhang; Yun-Qiang Tang; Bao-Hua Hou
Journal:  World J Gastroenterol       Date:  2020-05-21       Impact factor: 5.742

Review 2.  The functioning side of the pancreas: a review on insulinomas.

Authors:  I Maggio; V Mollica; N Brighi; G Lamberti; L Manuzzi; A D Ricci; D Campana
Journal:  J Endocrinol Invest       Date:  2019-07-31       Impact factor: 4.256

3.  G3 GEP NENs category: are basic and clinical investigations well integrated?

Authors:  Massimo Milione; Nicola Fazio
Journal:  Endocrine       Date:  2017-07-21       Impact factor: 3.633

Review 4.  Management of Well-Differentiated High-Grade (G3) Neuroendocrine Tumors.

Authors:  Mohamad Bassam Sonbol; Thorvardur R Halfdanarson
Journal:  Curr Treat Options Oncol       Date:  2019-08-19

5.  Prognostic factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): what's better?

Authors:  Massimo Milione
Journal:  Endocrine       Date:  2017-04-17       Impact factor: 3.633

Review 6.  Peptide Receptor Radiotherapy: Current Approaches and Future Directions.

Authors:  Grace Kong; Rodney J Hicks
Journal:  Curr Treat Options Oncol       Date:  2019-08-29

Review 7.  Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you?

Authors:  Andrew M Bellizzi
Journal:  Hum Pathol       Date:  2019-12-17       Impact factor: 3.466

8.  Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Opin Pharmacother       Date:  2018-05-24       Impact factor: 3.889

9.  Grade 3 Neuroendocrine Tumor (G3 NET) in a Background of Multiple Serotonin Cell Neoplasms of the Ileum Associated with Carcinoid Syndrome and Aggressive Behavior.

Authors:  Francesca Capuano; Oneda Grami; Luigi Pugliese; Marco Paulli; Andrea Pietrabissa; Enrico Solcia; Alessandro Vanoli
Journal:  Endocr Pathol       Date:  2018-12       Impact factor: 3.943

Review 10.  Neuroendocrine neoplasia of the gastrointestinal tract revisited: towards precision medicine.

Authors:  Guido Rindi; Bertram Wiedenmann
Journal:  Nat Rev Endocrinol       Date:  2020-08-24       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.